UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/529,457	03/28/2005	Herbert Pilgrimm	3975.042	8098
30448 7590 03/25/2009 AKERMAN SENTERFITT			EXAMINER	
P.O. BOX 3188		SCHLIENTZ, LEAH H		
WEST PALM BEACH, FL 33402-3188		58	ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			03/25/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/529,457	PILGRIMM, HERBERT
Office Action Summary	Examiner	Art Unit
	Leah Schlientz	1618
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perio- Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION (1.136(a). In no event, however, may a reply be to divide apply and will expire SIX (6) MONTHS froute, cause the application to become ABANDON	N. imely filed m the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 28. This action is FINAL . 2b) ☑ The 3) ☐ Since this application is in condition for allow closed in accordance with the practice under	is action is non-final. ance except for formal matters, p	
Disposition of Claims		
4) Claim(s) 1-15 is/are pending in the applicatio 4a) Of the above claim(s) is/are withdres 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-15 are subject to restriction and/or	rawn from consideration.	
Application Papers		
9) The specification is objected to by the Examir 10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examiration.	ccepted or b) objected to by the e drawing(s) be held in abeyance. Section is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority documents. Copies of the certified copies of the priority documents. See the attached detailed Office action for a list	nts have been received. nts have been received in Applica iority documents have been receiv au (PCT Rule 17.2(a)).	tion No ved in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Date

Art Unit: 1618

DETAILED ACTION

Page 2

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-10, 13 and 14 drawn to stabilized superparamagnetic particles.

Group II, claim(s) 11 and 12, drawn to a method for manufacture of stabilized superparamagnetic nanoparticles.

Group III, claim(s) 15, in part, drawn to a method for tumor destruction.

Group IV, claim(s) 15, in part, drawn to a method for combating inflammatory disease.

Group V, claim(s) 15, in part, drawn to a method for control of organ function.

Group VI, claim(s) 15, in part, drawn to a method for magnetic drug targeting.

Group VII, claim(s) 15, in part, drawn to a method for use as MRI contrast agents.

Group VIII, claim(s) 15, in part, drawn to a method for use as magnetic ion exchangers.

Group IX, claim(s) 15, in part, drawn to a method for in vitro diagnosis.

The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

An international application should relate to only one invention or, if there is more than one invention, the inclusion of those inventions in one international application is only permitted if all inventions are so linked as to form a single general inventive concept (PCT Rule 13.1). With respect to a group of inventions claimed in an international application, unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features.

The expression "special technical features" is defined in PCT Rule 13.2 as meaning those technical features that define a contribution which each of the inventions, considered as a whole, makes over the prior art. The determination is made on the contents of the claims as interpreted in light of the description and drawings (if any). Whether or not any particular technical feature makes a "contribution" over the prior art, and therefore constitutes a "special technical feature", should be considered with respect to novelty and inventive step.

The common technical feature in all the groups is superparamagnetic particles stabilized on the surface by means of aliphatic dicarbon or polycarbon acids, wherein the superparamagnetic single domain particles carry charged ions of chemical elements on their surface. This element cannot be a special technical feature under PCT Rule 13.2 because the element is shown in the prior art.

US 6,638,494 teaches superparamagnetic single domain particles including a stabilizer substance such as di and polycarboxylic acids (column 4, lines 55+), and further including additional stabilizer substances such as polyethyleneimine, phosphate,

Art Unit: 1618

sulfonate, etc. (column 5, lines 25+). As a result, no special technical features exist among the different groups because the invention in Group 1 fails to make a contribution over the prior art with respect to novelty or inventive step. In conclusion, there is lack of unity of inventions, and therefore restriction for examination purposes as indicated is proper.

Election of Species

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows: charged ions. The different structures included therein are a very diverse set and are independent and distinct structures, including copper, gold, technetium, ⁶⁷Ga, polyethyleneimine, ¹³N, ¹⁵O, etc. which control the classification, thus, necessitate a specific election to which the elected Group will be drawn.

Applicant is required, in reply to this action, to elect a single *specific* species of ion on which the preliminary search will be conducted, and to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include

all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a). The following claim(s) are generic: 1, 7-11, 13-15.

A telephone call was not made to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Notice of Potential Rejoinder

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

Page 6

Art Unit: 1618

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leah Schlientz whose telephone number is 571-272-9928. The examiner can normally be reached on Monday - Friday 8 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/529,457 Page 7

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618

LHS